Alnylam and Medison Pharma Partner to Commercialize RNAi Therapeutics in Israel
Alnylam Pharmaceuticals and Medison Pharma announced an exclusive agreement to commercialize ONPATTRO, the first-ever commercialized RNAi therapeutic, as well as other investigational therapeutics under development in the Alnylam RNAi portfolio.
“Our partnership with Medison marks an important step in our global commercial expansion and signals our intent to ensure that patients suffering from serious rare diseases have access to our medicines, regardless of location,” said Theresa Heggie, SVP and Head of Europe, Middle East and Africa, and Canada, Alnylam Pharmaceuticals. “Medison has a strong organization with a proven track record of commercializing orphan products successfully, together with an infrastructure uniquely suited to supporting patients suffering from rare diseases in Israel and providing access to our potentially transformational therapies. We look forward to partnering with Medison to bring ONPATTRO and potential future therapies to patients.”
“We are proud to partner and collaborate with Alnylam in Israel,” said Meir Jakobsohn, Founder and CEO, Medison Pharma. “Alnylam’s portfolio of ONPATTRO and potentially ground-breaking medicines in late stage development will strengthen our rare disease portfolio, fulfilling Medison’s vision to provide innovative treatments to patients in Israel. Patients with hATTR amyloidosis with polyneuropathy in Israel deserve to have the earliest possible access to novel new treatments and we look forward to making this a reality, beginning with ONPATTRO. Patients and physicians in Israel are waiting for potentially disease modifying treatments and we will do everything in our capabilities to secure their access.”
The agreement between Alnylam and Medison includes ONPATTRO, approved in the EU in August 2018 for the treatment of hATTR amyloidosis in adults with stage 1 or stage 2 polyneuropathy; givosiran, a late-stage investigational RNAi therapeutic for the treatment of acute hepatic porphyria (AHP); and lumasiran, a late-stage investigational RNAi therapeutic for the treatment of Primary Hyperoxaluria Type 1 (PH1). These medicines are not currently approved for use in Israel and givosiran and lumasiran have not yet been approved by any regulatory authority.